US · PSNL
Personalis, Inc.
- Sector
- Healthcare · Medical - Diagnostics & Research
- Headquarters
- Fremont, CA 94025
- Website
- personalis.com
Price · as of 2025-12-31
$5.78
Market cap 804.57M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $32.93 | +469.72% |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | $0.00 | $0.00 | |||
| 2019 | $8.69 | $384.61 | $17,187.12 | $0.00 | $0.00 |
| 2020 | $27.02 | $30.28 | $728.62 | $0.00 | $0.00 |
| 2021 | $8.37 | $20.79 | $3.66 | $0.00 | $0.00 |
| 2022 | $2.59 | $20.62 | $3.53 | $0.00 | $36.76 |
| 2023 | $1.65 | $20.96 | $1.20 | $0.00 | $0.00 |
| 2024 | $4.14 | $24.34 | $0.96 | $0.00 | $0.00 |
| 2025 | $9.06 | $32.93 |
AI valuation
Our deep-learning model estimates Personalis, Inc.'s (PSNL) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $32.93
- Current price
- $5.78
- AI upside
- +469.72%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| PSNL | Personalis, Inc. | $5.78 | 804.57M | +470% | — | — | — | -9.95 | 3.10 | — | -8.46 | — | 3.10 | 0.00% | — | — | -35.02% | -152.75% | -26.89% | 0.12 | -429.55 | 6.76 | 6.46 | 1.30 | -3358.00% | -10000.00% | 6994.00% | -9.83% | -1.89 | -137.82% | 0.00% | 0.00% | 5.59% | -6.82 | -7.56 | — | 3.95 |
| BFLY | Butterfly Network, Inc. | $3.79 | 957.36M | +668% | -29% | — | — | -12.35 | 4.85 | 9.75 | -12.15 | — | 5.05 | 46.85% | -88.53% | -78.95% | -42.25% | -104.05% | -27.89% | 0.09 | -58.00 | 3.83 | 2.72 | 1.97 | -882.00% | 1896.00% | -6386.00% | -1.69% | -0.20 | -19.32% | 0.00% | 0.00% | 7.02% | -9.47 | -51.01 | 8.39 | 1.64 |
| CDNA | CareDx, Inc | $18.76 | 964.88M | +90% | -24% | -84% | — | -46.78 | 3.30 | 2.63 | -1261.39 | — | 4.33 | 66.99% | -5.53% | -5.62% | -6.27% | -14.41% | -4.72% | 0.06 | — | 2.86 | 2.45 | 68.59 | -14301.00% | 1379.00% | 1443.00% | 3.62% | 0.47 | 24.76% | 0.00% | 0.00% | 8.79% | -40.03 | 23.29 | 2.22 | 4.19 |
| CSTL | Castle Biosciences, Inc. | $29.57 | 863.11M | +72% | -30% | -71% | — | -33.58 | 1.72 | 2.36 | 48.38 | — | 2.19 | 68.66% | -12.44% | -7.02% | -5.21% | -17.64% | -4.35% | 0.08 | -497.79 | 5.26 | 4.99 | -7.04 | -23387.00% | 366.00% | -2248.00% | 3.49% | 0.94 | 14.26% | 0.00% | 0.00% | 0.00% | -12.82 | 19.37 | 1.59 | 4.94 |
| EVH | Evolent Health, Inc. | $3.25 | 376.91M | +378% | -56% | — | +2,393% | -0.71 | 0.98 | 0.22 | -0.76 | -0.13 | -0.47 | 15.09% | -0.24% | -28.49% | -81.81% | -0.48% | -26.08% | 0.05 | -0.08 | 1.31 | 1.23 | 0.37 | 52593.00% | -2656.00% | -17759.00% | 1.16% | 0.10 | 0.52% | 2.72% | -1.90% | 194.02% | -62.28 | 58.08 | 0.15 | 0.25 |
| FLGT | Fulgent Genetics, Inc. | $15.33 | 473.89M | +1,814% | -46% | +66% | — | -7.09 | 0.39 | 1.35 | -2.21 | -17.85 | 0.43 | 40.56% | -19.10% | -18.75% | -5.49% | -6.54% | -5.07% | 0.00 | -821.75 | 6.48 | 4.95 | 1.08 | 3972.00% | 1383.00% | 54509.00% | -28.42% | -1.20 | -14.97% | 0.00% | 0.00% | 3.19% | -1.65 | -0.82 | 0.31 | 3.63 |
| GERN | Geron Corporation | $1.68 | 1.07B | +294,119% | -54% | — | — | -6.40 | 3.99 | 14.52 | -5.38 | — | 3.99 | 98.37% | -225.64% | -226.73% | -66.09% | 7931.16% | -35.34% | 0.43 | -9.39 | 5.56 | 5.04 | -0.28 | -1562.00% | 3238692.00% | 3009.00% | -19.62% | -2.48 | 10011.32% | 0.00% | 0.00% | 0.00% | -4.79 | -3.80 | 10.82 | -2.06 |
| MRVI | Maravai LifeSciences Hold… | $3.56 | 516.14M | +2,414% | -55% | — | +382% | -2.27 | 2.47 | 2.82 | -4.45 | — | -7.64 | 18.30% | -69.20% | -70.41% | -85.84% | -61.48% | -25.95% | 0.17 | -4.79 | 6.60 | 5.40 | 2.35 | -1429.00% | -2834.00% | 21867.00% | -13.50% | -1.28 | -34.44% | 0.00% | 0.00% | 44.99% | -2.66 | -4.84 | 1.84 | 0.89 |
| MYGN | Myriad Genetics, Inc. | $4.61 | 429.72M | +702% | -57% | — | — | — | 1.27 | 0.57 | -1.33 | — | 2.87 | 69.93% | -16.90% | -44.38% | 0.00% | -22.11% | 0.00% | 0.57 | -11.51 | 2.49 | 1.98 | -0.15 | 18085.00% | -156.00% | -10469.00% | 0.39% | 0.01 | 0.31% | 0.00% | — | 0.00% | -3.79 | 293.13 | 0.64 | -0.54 |
| RZLT | Rezolute, Inc. | $3.21 | 307.19M | — | — | — | — | -8.17 | 3.75 | — | -5.53 | — | 3.75 | 0.00% | — | — | -52.56% | 2059.39% | -48.28% | 0.01 | — | 14.37 | 14.09 | 1.16 | -2632.00% | — | 2041.00% | -11.36% | -5.80 | 1780.51% | 0.00% | 0.00% | 4.00% | -5.53 | -6.40 | — | 23.66 |
| TYRA | Tyra Biosciences, Inc. | $33.31 | 1.78B | — | — | — | — | -7.24 | 1.82 | — | -2.80 | — | 1.82 | 0.00% | — | — | -31.60% | -1368.86% | -29.34% | 0.02 | — | 23.81 | 23.53 | 0.83 | -679.00% | — | 3836.00% | -11.25% | -4.78 | -925.54% | 0.00% | 0.00% | 5.54% | -2.79 | -4.13 | — | 17.59 |
About Personalis, Inc.
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.
- CEO
- Christopher Hall
- Employees
- 228
- Beta
- 1.99
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $5.78) − 1 = — (DCF, example).